AVTX Projected Dividend Yield
Com Par $0.001/Avalo Therapeutics Inc ( NASDAQ : AVTX )Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. Co.'s lead asset is AVTX-009, an anti-IL-1? mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1? (IL-1?) with high affinity and neutralizes its activity. IL- 1? is a central driver in the inflammatory process. 21 YEAR PERFORMANCE RESULTS |
AVTX Dividend History Detail AVTX Dividend News AVTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |